Company profile
Madrigal Pharmaceuticals, Inc.
NASDAQ: MDGL · Healthcare · Biotechnology
#158 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
64CFH 57DQ 69GM —SS 85
v0.1 · 55/100 weight · provisional
↑ market scale, revenue growth (YoY) · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$1.1B
Rev growth YoY (TTM)
+256.8%
Net income (FY)
-$288.3M
Employees
915
as of 2026-08-05
Market cap
$11.7B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$958.4M$958.4M2025
Net income-$288.3M-$288.3M2025
Operating income-$300.1M-$300.1M2025
Total assets$1.3B$1.3B2025
Liabilities$656.9M$656.9M2025
Equity$602.7M$602.7M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY23
FY23
FY23
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Madrigal Pharmaceuticals, Inc.’s revenue?
Madrigal Pharmaceuticals, Inc. booked $958.4M in FY2025 revenue, growing 432% year over year — faster than 93% of Healthcare companies we track, at a -30.1% net margin.
Peers · Healthcare
WELL Health Technologies Corp.71BGuardant Health, Inc.65BClaritev Corporation61CThe Pennant Group, Inc.73BIonis Pharmaceuticals, Inc.71BInspire Medical Systems, Inc.78B+Neighbors
Montgomery →Key facts
CEOWilliam J. Sibold
SectorHealthcare
IndustryBiotechnology
HeadquartersWest Conshohocken, PA
ExchangeNASDAQ: MDGL
Employees915
IPO date2007-02-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.